Breaking News, Collaborations & Alliances

PharmAbcine Partners with Samsung Biologics for PMC-403

The antibody is expected to enter a global ophthalmological clinical trial in 2022.

By: Contract Pharma

Contract Pharma Staff

PharmAbcine Inc. has entered into a strategic partnership with Samsung Biologics for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders. Samsung will provide the full scope of its CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support.   PharmAbcine’s lead molecule, Olinvacimab, is in phase II clinical trials for a combination therapy to treat cancer with...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters